CRISPR Therapeutics is paying $25 million upfront to work on multiple siRNA targets with Sirius Tx with an early focus on the ...

Despite hitting a clinical “milestone,” Prime Medicine is shelving its sole clinical-stage genetic medicine. | Despite ...

Boehringer Ingelheim’s long-awaited phase 3 lung disease data received a muted reception from analysts who labelled ...

Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the company’s eye disease ...

The company has signed up to pay $256 million for 23andMe and nearly all of its assets, including its R&D services operations ...

Pfizer-backed CellCentric has secured $120 million in series C funds as the British biotech prepares to take its multiple ...

Recent lawsuits from nonprofits, state attorneys general, unions and local governments say the reorganizations and reductions ...

Apnimed’s star sleep apnea asset has hit the latest landmark on its march down victory road. | Apnimed’s star sleep apnea ...

| Tech transfer is conceptually a straightforward process, but it is fraught with minutiae and unknowns that can introduce ...

Armata Pharmaceuticals has posted early validation of its phage platform. The phase 1b/2a trial linked a bacteriophage ...

Applied Therapeutics’ rare disease drug has failed another late-stage clinical trial, adding to the woes of a candidate that ...

The FDA said it has issued its first official green light for a blood test to help diagnose Alzheimer’s disease, adding that ...